The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 Deficiency
Conditions: Ectonucleotide Pyrophosphatase/Phosphodiesterase1 Deficiency; Autosomal Recessive Hypophosphatemic Rickets; Generalized Arterial Calcification of Infancy Interventions: Drug: INZ-701; Drug: Control Arm (Conventional Therapy) Sponsor: Inozyme Pharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials